Current Initiatives › In-Silico to In-Vitro Translation

Closing the Computational Loop

Proposed Translation of Digital Twins to Physical Microphysiological Systems

All content on this page strictly reflects computational models and architectural proposals. Physical deployment of the microfluidic integration is pending future pilot phases.

The 99% Translational Gap

The traditional pharmaceutical pipeline is paralyzed by a profound “translational gap”. Experimental compounds that demonstrate perfect binding affinities in computer simulations or exceptional efficacy in legacy animal models frequently fail catastrophically when administered to human patients. In complex neurodegenerative diseases, this failure rate approaches 99%. To solve this, RZST has theoretically engineered an architecture proposed to bypass the animal model entirely.

The Moat: Proposing the Organ-on-a-Chip Integration

While our current architecture represents a rigorously validated computational simulation based on the frameworks of Kuo et al. and du Terrail et al., our designed future horizon requires physical grounding. We are proposing a high-fidelity pipeline engineered to directly couple the predictive outputs of our Multi-scale Protein Language Models (PLMs) with living human biology.

  1. The Digital Output: In our proposed sequence, the federated PLM will predict the exact molecular structure optimized to bind selectively to toxic proteinopathies, such as fibrillar alpha-synuclein.
  2. Physical Synthesis & Integration: The proposed molecule would then be physically synthesized and introduced into patient-derived Organ-on-a-Chip Microphysiological Systems (MPS).
  3. The Empirical Readout: The microfluidic chip is intended to physically measure target engagement and screen for critical predictive toxicology (e.g., hepatotoxicity via DeepDILI).
  4. Recursive Optimization: The physical biological data points generated by the chip would be converted back into mathematical loss gradients, feeding directly back into the PLM to refine the next generation of molecules in a continuous loop.

Architecting for Mechanistic Proof

This proposed closed-loop system is designed as a regulatory necessity. Under the FDA’s Plausible Mechanism Framework, marketing approval requires incontrovertible proof of target engagement. By proposing a pipeline that grounds our in-silico simulations with empirical in-vitro data from human microfluidics, we aim to provide the exact mechanistic proof required by regulators. This architectural blueprint perfectly aligns with the NIH’s July 2025 mandate to transition away from legacy animal testing, outlining a fast-tracked, bioethically sound pathway to clinical translation.

Explore the Architectural Blueprint

We are actively seeking partnerships with academic hubs, microfluidics labs, and BioDAOs ready to operationalize this closed-loop translation architecture.

Contact the Core

Or reach us directly at contact@rzst.org